In cancer, SRSF11 overexpression has been demonstrated in a limited number of malignancies, including CRC, HCC, gastric cancer, and glioma, where it regulates processes such as cell-cycle progression, telomerase activation, epithelial-mesenchymal transition (EMT), and drug resistance23, 24. Here, SRSF11 is linked to hepatocellular carcinoma.